343 related articles for article (PubMed ID: 12634892)
1. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
Trindade PT; Rouleau JL
Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
[TBL] [Abstract][Full Text] [Related]
2. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of vasopeptidase inhibitors.
Lapointe N; Rouleau JL
Can J Cardiol; 2002 Apr; 18(4):415-20. PubMed ID: 11992135
[TBL] [Abstract][Full Text] [Related]
5. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
Machowska A; Juszczak K; Novak P; Thor P
Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
[TBL] [Abstract][Full Text] [Related]
6. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
Floras JS
Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
[TBL] [Abstract][Full Text] [Related]
7. Combined neutral endopeptidase inhibitors.
Cuculi F; Erne P
Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
[TBL] [Abstract][Full Text] [Related]
9. Vasopeptidase inhibitors.
Weber MA
Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Nawarskas J; Rajan V; Frishman WH
Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
[TBL] [Abstract][Full Text] [Related]
11. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
Waeber B
Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
[TBL] [Abstract][Full Text] [Related]
12. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
13. Vasopeptidase inhibition: a double-edged sword?
Campbell DJ
Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
[TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibitors in heart failure.
Dawson A; Struthers AD
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
16. Current role of neprilysin inhibitors in hypertension and heart failure.
von Lueder TG; Atar D; Krum H
Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
[TBL] [Abstract][Full Text] [Related]
17. Vasopeptidase inhibitors: will they have a role in clinical practice?
Worthley MI; Corti R; Worthley SG
Br J Clin Pharmacol; 2004 Jan; 57(1):27-36. PubMed ID: 14678337
[TBL] [Abstract][Full Text] [Related]
18. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
[TBL] [Abstract][Full Text] [Related]
19. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
Burrell LM; Farina NK; Balding LC; Johnston CI
Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
[TBL] [Abstract][Full Text] [Related]
20. Vasopeptidase inhibitors.
Sagnella GA
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
